Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion

Blood

Volumn 101, Issue 12, 2003, Pages 4958-4965

  Gu, Jing Jin ^b   Gathy, Karen ^b   Santiago, Lalaine ^b   Chen, Eric ^b   Huang, Min ^b   Graves, Lee M ^b   Mitchell, Beverly S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; GUANINE NUCLEOTIDE; GUANOSINE; INOSINATE DEHYDROGENASE; INOSINATE DEHYDROGENASE INHIBITOR; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; MYCOPHENOLIC ACID; PHOSPHOTRANSFERASE; PROTEIN C JUN; PROTEIN P70; RAPAMYCIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 0038045031     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2547     Document Type: Article

References (42)

1. Zimmermann AG, Gu JJ, Laliberte J, Mitchell BS. Inosine-5′-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol. 1998;61:181-209.
2. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990;265:5292-5295.
3. Senda M, Natsumeda Y. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E. C. 1. 1. 1. 205). Life Sci. 1994;54:1917-1926.
4. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S, Weber G. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 1991;51:3886-3890.
5. Nagai M, Natsumeda Y, Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res. 1992;52:258-261.
6. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest. 1991;87:940-948.
7. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol. 1991;33:161-173.
8. Eugui EM, Mirkovich A, Allison AC. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice [erratum appears in Scand J Immunol. 1998;48:45]. Scand J Immunol. 1991;33:175-183.
9. Jain J, Almquist SJ, Shlyakhter D, Harding MW. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001;90:625-637.
10. Yashima Y, Ohgane T. Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent [in Japanese]. Nippon Yakurigaku Zasshi. 2001;117:131-137.
11. Mookerjee B. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus [see comments]. Bone Marrow Transplant. 1999;24:517-520.
12. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265-268.
13. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyanglitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999;10:1965-1971.
14. Olah E, Kote Z, Natsumeda Y, et al. Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells. Cancer Biochem Biophys. 1990;11:107-117.
15. Laliberte J, Yee A, Xiong Y, Mitchell BS. Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood. 1998;91:2896-2904.
16. Olah E, Natsumeda Y, Ikegami T, et al. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells. Proc Natl Acad Sci U S A. 1988;85:6533-6537.
17. Kharbanda SM, Sherman ML, Kufe DW. Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells. Blood. 1990;75:583-588.
18. Yu J, Lemas V, Page T, Connor JD, Yu AL. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase. Cancer Res. 1989;49:5555-5560.
19. Inai K, Tsutani H, Yamauchi T, Nakamura T, Ueda T. Differentiation and reduction of intracellular GTP levels in HL-60 and U937 cells upon treatment with IMP dehydrogenase inhibitors. Adv Exp Med Biol. 1998;431:549-553.
20. Vitale M, Zamai L, Falcieri E, et al. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Cytometry. 1997;30:61-66.
21. Li G, Segu VB, Rabaglia ME, Luo RH, Kowluru A, Metz SA. Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology. 1998;139:3752-3762.
22. Qiu Y, Fairbanks LD, Ruckermann K, et al. Mycophenolic acid-induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation. 2000;69:890-897.
23. Brunn GJ, Hudson CO, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997;277:99-101.
24. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4EBP1. Proc Natl Acad Sci U S A. 1998;95:1432-1437.
25. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science. 2001;294:1102-1105.
26. Reddy EP, Korapati A, Chaturvedi P, Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene. 2000;19:2532-2547.
27. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995;82:241-250.
28. Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol. 2000;10:47-50.
29. Haq R, Halupa A, Beattie BK, Mason JM, Zanke BW, Barber DL. Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem. 2002;277:17359-17366.
30. Tricot GJ, Jayaram HN, Lapis E, et al. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity. Cancer Res. 1989;49:3696-3701.
31. Satoh T, Nakafuku M, Miyajima A, Kaziro Y. Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci U S A. 1991;88:3314-3318.
32. Duronio V, Welham MJ, Abraham S, Dryden P, Schrader JW. p21 ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21 ras GTPase-activating protein. Proc Natl Acad Sci U S A. 1992;89:1587-1591.
33. Cleveland JL, Troppmair J, Packham G, et al. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene. 1994;9:2217-2226.
34. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J. 1995;14:266-275.
35. Suzuki J, Kaziro Y, Koide H. An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I. Oncogene. 1997;15:1689-1697.
36. Casey PJ, Gilman AG. G protein involvement in receptor-effector coupling. J Biol Chem. 1988;263:2577-2580.
37. Otero AD. Transphosphorylation and G protein activation. Biochem Pharmacol. 1990;39:1399-1404.
38. Schmelzie T. TOR, a central controller of cell growth [see comments]. Cell. 2000;103:253-262.
39. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807-826.
40. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol. 1998;10:268-275.
41. Davis RJ. Signal transduction by the JNK group of MAP kinases [see comments]. Cell. 2000;103:239-252.
42. Towatari M, Iida H, Tanimoto M, Iwata H, Hamaguchi M, Saito H. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479-484.